Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Clinical trial NCT05537766 · TERMINATED

Trial details

NCT number: NCT05537766
Sponsor: Kite, A Gilead Company
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Waldenstrom Macroglobulinemia Relapsed/Refractory Richter Transformation Relapsed/Refractory Burkitt Lymphoma Relapsed/Refractory Hairy Cell Leukemia

Start date: 2022-11-01
Primary completion: 2025-01-27
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.